E. Yekedüz Et Al. , "Sorafenib in Radioactive Iodine Refractory Differentiated Thyroid Cancer: A Real-life Data with Long-term Experience," Ankara Üniversitesi Tıp Fakültesi Mecmuası , vol.75, no.1, pp.103-106, 2022
Yekedüz, E. Et Al. 2022. Sorafenib in Radioactive Iodine Refractory Differentiated Thyroid Cancer: A Real-life Data with Long-term Experience. Ankara Üniversitesi Tıp Fakültesi Mecmuası , vol.75, no.1 , 103-106.
Yekedüz, E., Köksoy, E. B., Şenler, F., Akbulut, H., Demirkazık, A., Ürün, Y., ... Utkan, G.(2022). Sorafenib in Radioactive Iodine Refractory Differentiated Thyroid Cancer: A Real-life Data with Long-term Experience. Ankara Üniversitesi Tıp Fakültesi Mecmuası , vol.75, no.1, 103-106.
Yekedüz, EMRE Et Al. "Sorafenib in Radioactive Iodine Refractory Differentiated Thyroid Cancer: A Real-life Data with Long-term Experience," Ankara Üniversitesi Tıp Fakültesi Mecmuası , vol.75, no.1, 103-106, 2022
Yekedüz, EMRE Et Al. "Sorafenib in Radioactive Iodine Refractory Differentiated Thyroid Cancer: A Real-life Data with Long-term Experience." Ankara Üniversitesi Tıp Fakültesi Mecmuası , vol.75, no.1, pp.103-106, 2022
Yekedüz, E. Et Al. (2022) . "Sorafenib in Radioactive Iodine Refractory Differentiated Thyroid Cancer: A Real-life Data with Long-term Experience." Ankara Üniversitesi Tıp Fakültesi Mecmuası , vol.75, no.1, pp.103-106.
@article{article, author={EMRE YEKEDÜZ Et Al. }, title={Sorafenib in Radioactive Iodine Refractory Differentiated Thyroid Cancer: A Real-life Data with Long-term Experience}, journal={Ankara Üniversitesi Tıp Fakültesi Mecmuası}, year=2022, pages={103-106} }